Off-targets

Off-targets refer to the unintended biological molecules, typically proteins, that a drug or therapeutic agent binds to in addition to its primary intended target (Bowes et al., 2012). These interactions often occur due to structural similarities between the intended target and other proteins or the inherent promiscuity of the drug molecule (Peters, 2013). While some off-target interactions may be therapeutically beneficial, a phenomenon known as polypharmacology, they are more commonly associated with adverse drug reactions, toxicity, and side effects that can limit a drug's safety profile (Lounkine et al., 2012). Identifying and minimizing off-target activity is a critical component of the drug discovery and development process to ensure clinical safety and efficacy. Common examples include the hERG potassium channel, which is a frequent off-target associated with cardiotoxicity and QT interval prolongation (Sanguinetti & Tristani-Firouzi, 2006). Modern drug discovery utilizes broad pharmacological profiling and computational modeling to predict these interactions early in development to mitigate risks before human trials (Lin et al., 2019). Off-target effects can also lead to drug repurposing opportunities if the secondary interaction is found to be relevant to a different disease state. However, the primary focus in safety pharmacology remains the avoidance of "anti-targets" that cause significant harm to patients. Regulatory agencies often require extensive screening against panels of known off-targets before a drug can proceed to clinical trials. Ultimately, understanding the off-target landscape of a lead compound is essential for balancing potency against the intended target with a manageable safety margin.

Other names

Non-specific targetsUnintended targetsSecondary targetsAnti-targetsPromiscuous targets

Off-targets involve the unintended binding or modulation of biological molecules (receptors, enzymes, ion channels) other than the primary therapeutic target, typically driven by molecular promiscuity or structural homology between proteins (Bowes et al., 2012; Peters, 2013).